FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890591279> ?p ?o ?g. }

• W2890591279 endingPage "9021" @default.
• W2890591279 startingPage "9021" @default.
• W2890591279 abstract "9021 Background: In the double-blind, phase 3 KEYNOTE-189 study (NCT02578680), pembro + pem + plt significantly improved OS and PFS over pbo + pem + plt as first-line therapy for nonsquamous NSCLC. Grade 3-5 drug-related AE rates were higher with pembro. We report the prespecified patient-reported outcome (PRO) analyses from KEYNOTE-189. Methods: 616 patients (pts) were randomized to pembro 200 mg Q3W or pbo for 2 y; all pts received pem + 4 cycles of carboplatin or cisplatin. The EORTC QLQ-C30 and QLQ-LC13 were administered at cycles 1-5, then every 3 cycles during yr 1 and every 4 cycles during yrs 2 and 3. Key PRO outcomes were change from baseline to wks 12 and 21 in the QLQ-C30 global health status/QoL score and time to deterioration in the composite of cough, chest pain, or dyspnea. PROs were analyzed in all treated pts who completed ≥1 PRO instrument (n = 602). P values are nominal and 2-sided. Results: QLQ-C30 and QLQ-LC13 compliance was ~90% at baseline and wk 12 in both arms and was ~75% with pembro and ~63% with pbo at wk 21. Mean baseline scores were 61.98 and 60.56 in the pembro and pbo arms. At wks 12 and 21, global health status/QoL scores were stable with pembro and decreased with pbo, with significantly greater decrement with pbo at wk 21 (Table). The proportion of improved global health status/QoL was similar at wk 12 (28.9% with pembro vs 26.5% with pbo; P = .5450) but was greater with pembro at wk 21 (30.1% vs 22.5%; P = .0496). Median time to deterioration in the composite of cough, chest pain, or dyspnea was NR with pembro (95% CI 10.2 mo-NR) vs 7.0 mo (95% CI, 4.8-NR) with pbo (HR 0.81; 95% CI 0.60-1.09; nominal 2-sided P = .081). Conclusions: In this double-blind trial, pembro + pem + plt maintained or improved HRQoL over pem + plt alone despite a higher grade 3-5 treatment-related AE rate. Along with superior efficacy, these data support the use of pembro + pem + plt as first-line therapy for metastatic nonsquamous NSCLC. Clinical trial information: NCT02578680." @default.
• W2890591279 created "2018-09-27" @default.
• W2890591279 creator A5004864286 @default.
• W2890591279 creator A5012226414 @default.
• W2890591279 creator A5020504047 @default.
• W2890591279 creator A5025836672 @default.
• W2890591279 creator A5033474030 @default.
• W2890591279 creator A5055278162 @default.
• W2890591279 creator A5055964030 @default.
• W2890591279 creator A5060287300 @default.
• W2890591279 creator A5060572768 @default.
• W2890591279 creator A5068743826 @default.
• W2890591279 creator A5073432388 @default.
• W2890591279 creator A5073870135 @default.
• W2890591279 creator A5075054175 @default.
• W2890591279 creator A5077287358 @default.
• W2890591279 creator A5080841299 @default.
• W2890591279 creator A5084614193 @default.
• W2890591279 creator A5086954528 @default.
• W2890591279 creator A5087125249 @default.
• W2890591279 creator A5090324173 @default.
• W2890591279 creator A5091509029 @default.
• W2890591279 date "2018-05-20" @default.
• W2890591279 modified "2023-10-16" @default.
• W2890591279 title "Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) + pemetrexed (pem) + platinum (plt) for metastatic NSCLC." @default.
• W2890591279 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.9021" @default.
• W2890591279 hasPublicationYear "2018" @default.
• W2890591279 type Work @default.
• W2890591279 sameAs 2890591279 @default.
• W2890591279 citedByCount "13" @default.
• W2890591279 countsByYear W28905912792019 @default.
• W2890591279 countsByYear W28905912792020 @default.
• W2890591279 countsByYear W28905912792022 @default.
• W2890591279 crossrefType "journal-article" @default.
• W2890591279 hasAuthorship W2890591279A5004864286 @default.
• W2890591279 hasAuthorship W2890591279A5012226414 @default.
• W2890591279 hasAuthorship W2890591279A5020504047 @default.
• W2890591279 hasAuthorship W2890591279A5025836672 @default.
• W2890591279 hasAuthorship W2890591279A5033474030 @default.
• W2890591279 hasAuthorship W2890591279A5055278162 @default.
• W2890591279 hasAuthorship W2890591279A5055964030 @default.
• W2890591279 hasAuthorship W2890591279A5060287300 @default.
• W2890591279 hasAuthorship W2890591279A5060572768 @default.
• W2890591279 hasAuthorship W2890591279A5068743826 @default.
• W2890591279 hasAuthorship W2890591279A5073432388 @default.
• W2890591279 hasAuthorship W2890591279A5073870135 @default.
• W2890591279 hasAuthorship W2890591279A5075054175 @default.
• W2890591279 hasAuthorship W2890591279A5077287358 @default.
• W2890591279 hasAuthorship W2890591279A5080841299 @default.
• W2890591279 hasAuthorship W2890591279A5084614193 @default.
• W2890591279 hasAuthorship W2890591279A5086954528 @default.
• W2890591279 hasAuthorship W2890591279A5087125249 @default.
• W2890591279 hasAuthorship W2890591279A5090324173 @default.
• W2890591279 hasAuthorship W2890591279A5091509029 @default.
• W2890591279 hasConcept C121608353 @default.
• W2890591279 hasConcept C126322002 @default.
• W2890591279 hasConcept C142724271 @default.
• W2890591279 hasConcept C159110408 @default.
• W2890591279 hasConcept C204787440 @default.
• W2890591279 hasConcept C27081682 @default.
• W2890591279 hasConcept C2776256026 @default.
• W2890591279 hasConcept C2776694085 @default.
• W2890591279 hasConcept C2777240266 @default.
• W2890591279 hasConcept C2777701055 @default.
• W2890591279 hasConcept C2778239845 @default.
• W2890591279 hasConcept C2779951463 @default.
• W2890591279 hasConcept C2780057760 @default.
• W2890591279 hasConcept C2781451048 @default.
• W2890591279 hasConcept C535046627 @default.
• W2890591279 hasConcept C71924100 @default.
• W2890591279 hasConceptScore W2890591279C121608353 @default.
• W2890591279 hasConceptScore W2890591279C126322002 @default.
• W2890591279 hasConceptScore W2890591279C142724271 @default.
• W2890591279 hasConceptScore W2890591279C159110408 @default.
• W2890591279 hasConceptScore W2890591279C204787440 @default.
• W2890591279 hasConceptScore W2890591279C27081682 @default.
• W2890591279 hasConceptScore W2890591279C2776256026 @default.
• W2890591279 hasConceptScore W2890591279C2776694085 @default.
• W2890591279 hasConceptScore W2890591279C2777240266 @default.
• W2890591279 hasConceptScore W2890591279C2777701055 @default.
• W2890591279 hasConceptScore W2890591279C2778239845 @default.
• W2890591279 hasConceptScore W2890591279C2779951463 @default.
• W2890591279 hasConceptScore W2890591279C2780057760 @default.
• W2890591279 hasConceptScore W2890591279C2781451048 @default.
• W2890591279 hasConceptScore W2890591279C535046627 @default.
• W2890591279 hasConceptScore W2890591279C71924100 @default.
• W2890591279 hasIssue "15_suppl" @default.
• W2890591279 hasLocation W28905912791 @default.
• W2890591279 hasOpenAccess W2890591279 @default.
• W2890591279 hasPrimaryLocation W28905912791 @default.
• W2890591279 hasRelatedWork W2529904548 @default.
• W2890591279 hasRelatedWork W2562994637 @default.
• W2890591279 hasRelatedWork W2570157415 @default.
• W2890591279 hasRelatedWork W2765111236 @default.
• W2890591279 hasRelatedWork W2809866417 @default.
• W2890591279 hasRelatedWork W2981688104 @default.
• W2890591279 hasRelatedWork W2988616663 @default.
• W2890591279 hasRelatedWork W4206483067 @default.

• next